Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
IMpower132: atezolizumab, carboplatin and pemetrexed as first line treatment in key subgroups with stage IV non-squamous NSCLC

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.10.18
Views: 1364

Dr Fabrice Barlesi - Aix-Marseille University, Marseille, France

Dr Fabrice Barlesi speaks with ecancer at ESMO 2018 in Munich about results from a study on using atezolizumab, carboplatin and pemetrexed as first line treatments for specific sub-groups of patients with stage IV non-squamous NSCLC.

Dr Barlesi explains that one advantage found was a superiority in the combination of immunotherapy and chemotherapy over the standard chemotherapy in all subgroups bar patients with liver metastasis.

He goes on to explain that there was some difference in activity in the asian population included in the study, but investigation into the biomarkers is still ongoing.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation